Brief: Bukwang Pharmaceutical Ind Receives Market Approval For Its New Atypical Antipsychotic Drug ‘Latuda Tablets’ From South Korea’S Ministry Of Food And Drug Safety
23/11/2023 14:59
Bukwang Pharm Co Ltd 003000.KS :
* BUKWANG PHARMACEUTICAL IND: RECEIVES MARKET APPROVAL FOR
ITS NEW
ATYPICAL ANTIPSYCHOTIC DRUG ‘LATUDA TABLETS’ FROM SOUTH KOREA’S
MINISTRY OF FOOD AND DRUG SAFETY
Source text for Eikon: ID:
Further company coverage: 003000.KS
Recent news on Bukwang Pharm
See all newsQ2 2026 Operating Profit Up 27.6% QoQ, Down 30.0% YoY To Won 1.41 Billion
Brief: Bukwang Pharm Q1 Operating Profit 1 Billion Won, Down 62.6% From Year Earlier
Brief: Bukwang Pharmaceutical Ind Q3 Operating Profit 979 Million Won, Down 69.3% From Year Earlier
Brief: Bukwang Pharmaceutical Ind Q2 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Bukwang Pharmaceutical Ind Q1 Operating Profit 3 Billion Won, Swings To Profit From Year Earlier